ePrints

What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease

Lookup NU author(s): Dr Salman Razvi, Dr Bijayeswar Vaidya, Dr Petros PerrosORCiD, Professor Simon PearceORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Block-replace and titration antithyroid drug regimens both give similar rates of medium- to long-term remission of hyperthyroid Graves' disease. Recent meta-analysis, however, has suggested that titration regimens may be preferable owing to a higher rate of adverse events seen in the block-replace arms of published comparative studies. This article critically re-evaluates the evidence upon which these meta-analyses were based. We suggest that there is little objective evidence that is pertinent to current clinical practice to separate block-replace from titration antithyroid drug regimens and that both remain satisfactory approaches to the medical management of hyperthyroid Graves' disease. © 2006 Society of the European Journal of Endocrinology.

Publication metadata

Author(s): Razvi S, Vaidya B, Perros P, Pearce SHS

Publication type: Article

Publication status: Published

Journal: European Journal of Endocrinology

Year: 2006

Volume: 154

Issue: 6

Pages: 783-786

ISSN (print): 0804-4643

ISSN (electronic): 1479-683X

Publisher: BioScientifica Ltd.

URL: http://dx.doi.org/10.1530/eje.1.02169

DOI: 10.1530/eje.1.02169

PubMed id: 16728536

Altmetrics

Share